Company news

MeiraGTx Holdings plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.

November 9, 2022

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

October 3, 2022

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

September 30, 2022

MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

September 15, 2022

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

August 10, 2022

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

August 2, 2022

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared...

June 27, 2022

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

May 11, 2022

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

May 3, 2022

MeiraGTx Appoints Debra Yu, MD to Board of Directors

April 26, 2022

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

April 18, 2022

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

March 9, 2022

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

January 26, 2022

MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation

December 13, 2021

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

December 6, 2021

MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation

November 28, 2021

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results

November 9, 2021

MeiraGTx to Participate in Upcoming Virtual Investor Conferences

November 8, 2021

MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platform at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress

October 18, 2021

MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference

September 27, 2021

MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa

September 8, 2021

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

August 10, 2021

MeiraGTx Reports First Quarter 2021 Financial and Operational Results

May 10, 2021

MeiraGTx Announces Participation at Upcoming Investor Conferences

May 4, 2021

MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit

April 18, 2021

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

March 10, 2021

MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference

March 3, 2021

MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia

January 25, 2021

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

December 15, 2020

MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

November 29, 2020

MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 22, 2020

MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

November 18, 2020

MeiraGTx Announces Proposed Public Offering of Ordinary Shares

November 17, 2020

MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment

November 12, 2020

MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit

November 9, 2020

MeiraGTx Reports Third Quarter 2020 Financial Results

November 4, 2020

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting

October 27, 2020

MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)

October 2, 2020

MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference

September 27, 2020

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting

September 21, 2020

MeiraGTx Reports Second Quarter 2020 Financial Results

August 5, 2020

MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer

August 4, 2020

MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients

July 16, 2020

MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders

May 25, 2020

MeiraGTx Reports First Quarter 2020 Financial Results

May 6, 2020

MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference

May 5, 2020

MeiraGTx Reports Full Year 2019 Financial Results

March 10, 2020

MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

March 1, 2020

MeiraGTx to Present at Upcoming Investor Conferences

February 23, 2020

MeiraGTx to Host Parkinson’s Disease R&D Day in New York

December 4, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.